Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretroviral agents

被引:14
作者
Hoggard, PG [1 ]
Lloyd, J
Khoo, SH
Barry, MG
Dann, L
Gibbons, SE
Wilkins, EG
Loveday, C
Back, DJ
机构
[1] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England
[2] Royal Free Hosp, Sch Med, Dept Retrovirol, London NW3 2QG, England
[3] N Manchester Gen Hosp, Dept Infect Dis, Manchester M8 5RB, Lancs, England
[4] St James Hosp, Trinity Coll Hlth Sci, Dept Pharmacol & Therapeut, Dublin 8, Ireland
关键词
D O I
10.1128/AAC.35.3.976-980.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We sought to determine whether the intracellular activation of zidovudine (ZDV) varied over time and with previous antiretroviral exposure in human immunodeficiency virus-infected individuals and to examine whether there is an association between virological responses and intracellular phosphorylation. A total of 23 patients (12 treatment naive, 11 previously treated with ZDV) who commenced ZDV as part of dual nucleoside therapy were prospectively monitored for 12 months or until withdrawal from the study. No association was observed between virological responses at 2 weeks and 3 months and ZDV phosphorylation. The mean intracellular concentrations of ZDV mono-, di-, and triphosphates did not change significantly over time or with previous ZDV exposure. The rate of formation of total ZDV phosphates was increased in patients with CD4 counts < 100 cells/mm(3). Previous reports from in vitro cell culture experiments or cross-sectional cohort studies suggesting alterations of ZDV phosphorylation over time are not confirmed by this longitudinal study.
引用
收藏
页码:976 / 980
页数:5
相关论文
共 14 条
[1]   Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase [J].
Antonelli, G ;
Turriziani, O ;
Verri, A ;
Narciso, P ;
Ferri, F ;
DOffizi, G ;
Dianzani, F .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (03) :223-228
[2]  
AVRAMIS VI, 1993, J ACQ IMMUN DEF SYND, V6, P1287
[3]   ZIDOVUDINE PHOSPHORYLATION IN HIV-INFECTED PATIENTS AND SERONEGATIVE VOLUNTEERS [J].
BARRY, M ;
WILD, M ;
VEAL, G ;
BACK, D ;
BRECKENRIDGE, A ;
FOX, R ;
BEECHING, N ;
NYE, F ;
CAREY, P ;
TIMMINS, D .
AIDS, 1994, 8 (08) :F1-F5
[4]   The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites [J].
Barry, MG ;
Khoo, SH ;
Veal, GJ ;
Hoggard, PG ;
Gibbons, SE ;
Wilkins, EGL ;
Williams, O ;
Breckenridge, AM ;
Back, DJ .
AIDS, 1996, 10 (12) :1361-1367
[5]   Determinants of virological response to antiretroviral therapy: Implications for long-term strategies [J].
Deeks, SG .
CLINICAL INFECTIOUS DISEASES, 2000, 30 :S177-S184
[6]  
GAO WY, 1994, MOL PHARMACOL, V46, P767
[7]   DECREASED THYMIDINE KINASE LEVELS IN PERIPHERAL-BLOOD CELLS FROM HIV-SEROPOSITIVE INDIVIDUALS - IMPLICATIONS FOR ZIDOVUDINE METABOLISM [J].
JACOBSSON, B ;
BRITTON, S ;
HE, QM ;
KARLSSON, A ;
ERIKSSON, S .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 (07) :805-811
[8]   HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE-1 REPLICATION [J].
LORI, F ;
MALYKH, A ;
CARA, A ;
SUN, D ;
WEINSTEIN, JN ;
LISZIEWICZ, J ;
GALLO, RC .
SCIENCE, 1994, 266 (5186) :801-805
[9]   Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus [J].
Peter, K ;
Gambertoglio, JG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (02) :168-176
[10]  
Phiboonbanakit D., 1998, British Journal of Clinical Pharmacology, V46, p294P